BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38138884)

  • 1. Do Tumor SURVIVIN and MDM2 Expression Levels Correlate with Treatment Response and Clinical Outcome in Isolated Limb Perfusion for In-Transit Cutaneous Melanoma Metastases?
    Russano F; Del Fiore P; Cassalia F; Benna C; Dall'Olmo L; Rastrelli M; Mocellin S
    J Pers Med; 2023 Nov; 13(12):. PubMed ID: 38138884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated Limb Perfusion and Immunotherapy in the Treatment of In-Transit Melanoma Metastases: Is It a Real Synergy?
    Rastrelli M; Russano F; Cavallin F; Del Fiore P; Pacilli C; Di Prata C; Rossi CR; Vecchiato A; Dall'Olmo L; Mocellin S
    J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.
    Deroose JP; Grünhagen DJ; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
    Br J Surg; 2011 Nov; 98(11):1573-80. PubMed ID: 21739427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
    In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
    Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
    Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion.
    Bagge AS; Ben-Shabat I; Belgrano V; Olofsson Bagge R
    Ann Surg Oncol; 2016 Jun; 23(6):2062-9. PubMed ID: 26868956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
    Olofsson R; Mattsson J; Lindnér P
    Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
    Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
    Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.
    Moreno-Ramirez D; de la Cruz-Merino L; Ferrandiz L; Villegas-Portero R; Nieto-Garcia A
    Oncologist; 2010; 15(4):416-27. PubMed ID: 20348274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
    Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
    Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial.
    Rossi CR; Russano F; Mocellin S; Chiarion-Sileni V; Foletto M; Pilati P; Campana LG; Zanon A; Picchi GF; Lise M; Nitti D
    Ann Surg Oncol; 2008 Apr; 15(4):1218-23. PubMed ID: 18247095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
    Belgrano V; Pettersson J; Nilsson JA; Mattsson J; Katsarelias D; Olofsson Bagge R
    Ann Surg Oncol; 2019 Apr; 26(4):1055-1062. PubMed ID: 30617871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
    Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
    Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
    Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.